MERRIMACK PHARMACEUTICALS INC Quarterly Operating Income (Loss) in USD from Q1 2011 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Merrimack Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2011 to Q1 2024.
  • Merrimack Pharmaceuticals Inc Operating Income (Loss) for the quarter ending March 31, 2024 was -$669K, a 49.7% decline year-over-year.
  • Merrimack Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending March 31, 2024 was -$2.26M, a 10.5% decline year-over-year.
  • Merrimack Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$2.04M, a 17.8% decline from 2022.
  • Merrimack Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$1.73M, a 30.1% increase from 2021.
  • Merrimack Pharmaceuticals Inc annual Operating Income (Loss) for 2021 was -$2.47M, a 14% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$2.26M -$669K -$222K -49.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$2.04M -$490K +$117K +19.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$2.15M -$531K -$27K -5.36% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$2.13M -$569K -$83K -17.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$2.04M -$447K -$315K -239% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$1.73M -$607K -$134K -28.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$1.6M -$504K +$21K +4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$1.62M -$486K +$292K +37.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$1.91M -$132K +$564K +81% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$2.47M -$473K +$413K +46.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$2.89M -$525K +$482K +47.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$3.37M -$778K +$406K +34.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$3.77M -$696K -$900K -441% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$2.87M -$886K +$1.33M +59.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-09
Q3 2020 -$4.2M -$1.01M -$161K -19% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$4.04M -$1.18M +$8.07M +87.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$12.1M $204K +$10.2M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$22.4M -$2.21M +$12.1M +84.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 -$34.4M -$846K +$15.9M +94.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$50.3M -$9.26M +$7.93M +46.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$58.2M -$10M +$7.33M +42.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$65.6M -$14.3M +$2.74M +16.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$68.3M -$16.7M +$228K +1.34% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$68.5M -$17.2M +$17.4M +50.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-17
Q1 2018 -$85.9M -$17.4M +$9.86M +36.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$95.8M -$17M +$24.5M +59% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$120M -$17M +$18.5M +52.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$139M -$34.5M +$1.28M +3.58% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$140M -$27.2M +$7.22M +20.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 -$147M -$41.5M +$16.7M +28.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$164M -$35.5M +$2.78M +7.25% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$167M -$35.8M -$17.3M -93% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$150M -$34.5M -$4.43M -14.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 -$145M -$58.2M -$89.6M -286% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-12
Q3 2015 -$55.5M -$38.3M -$14.6M -61.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 -$41M -$18.6M -$4.66M -33.5% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 -$36.3M -$30M -$6.51M -27.7% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 -$29.8M $31.4M +$59.6M Oct 1, 2014 Dec 31, 2014 8-K 2017-12-15
Q3 2014 -$89.4M -$23.7M +$12.2M +34% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 -$102M -$13.9M +$15.2M +52.2% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$117M -$23.5M +$3.75M +13.8% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 -$121M -$28.2M -$3.71M -15.1% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-26
Q3 2013 -$117M -$35.9M -$12.1M -50.5% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 -$105M -$29.1M -$8.8M -43.4% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$96M -$27.3M -$3.23M -13.4% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-06
Q4 2012 -$92.7M -$24.5M -$6.36M -35% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-27
Q3 2012 -$86.4M -$23.9M -$5.24M -28.1% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 -$81.1M -$20.3M +$9.12M +31% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-08
Q1 2012 -$90.3M -$24M -$9.39M -64.2% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 -$80.9M -$18.2M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-04
Q3 2011 -$18.6M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$29.4M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$14.6M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.